Received Apr 5, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | X2TC2 | — |
administered a Bexsero vaccine to a pregnant patient; This non-serious prospective pregnancy case was reported by a other health professional via call center representative and described the occurrence of vaccine exposure during pregnancy in a 24-year-old female patient who received Men B NVS (Bexsero) (batch number X2TC2) for prophylaxis. On 27-MAR-2026, the patient received Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced vaccine exposure during pregnancy (Verbatim: administered a Bexsero vaccine to a pregnant patient). The outcome of the vaccine exposure during pregnancy was not applicable. Pregnancy exposure: Gestation time at first exposure (Bexsero): 4 Weeks Pregnancy Exposure (Bexsero): To mother in first trimester Last Menstrual Period Date: 22-FEB-2026 Estimated Delivery/Due date: 29-NOV-2026 Pregnancy Outcome: Pregnancy was ongoing This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-MAR-2026 The reporter reported that a Bexsero vaccine was administered to a pregnant patient, they need to know any contraindications.